Correction: Improving the Endocannabinoid System for Addressing Residual Disease in Multiple Sclerosis Without Relapses - Quiz - MDSpire

Correction: Improving the Endocannabinoid System for Addressing Residual Disease in Multiple Sclerosis Without Relapses

  • By

  • Pietro Annovazzi

  • Marinella Clerico

  • Eleonora Cocco

  • Antonella Conte

  • Girolama Alessandra Marfia

  • Marco Salvetti

  • Valentina Tomassini

  • Rocco Totaro

  • Diego Centonze

  • April 28, 2026

  • 0 min

Share

Original Source(s)

Correction: Improving the Endocannabinoid System for Addressing Residual Disease in Multiple Sclerosis Without Relapses

  • by Pietro Annovazzi, Marinella Clerico, Eleonora Cocco, Antonella Conte, Girolama Alessandra Marfia, Marco Salvetti, Valentina Tomassini, Rocco Totaro, Diego Centonze

  • April 28, 2026

Related Content

Physical disability, cognition, and depression as determinants of quality of life in multiple sclerosis: a cross-sectional study

Bile acid metabolomics reveals distinct immunometabolic niches and enables accurate diagnosis of AQP4-IgG–seronegative NMOSD

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.